Post-Approval Evaluation of Effectiveness of Risk Minimisation: Methods, Challenges and Interpretation
- 20 December 2013
- journal article
- review article
- Published by Springer Science and Business Media LLC in Drug Safety
- Vol. 37 (1), 33-42
- https://doi.org/10.1007/s40264-013-0126-7
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Additional risk minimisation measures in the EU- are they eligible for assessment?Pharmacoepidemiology and Drug Safety, 2013
- If You Don’t Know Where You Are Going, You Can’t Tell If You Have Arrived: Defining Goals for Drug Safety AnnouncementsClinical Pharmacology & Therapeutics, 2013
- When Direct Health-Care Professional Communications Have an Impact on Inappropriate and Unsafe Use of MedicinesClinical Pharmacology & Therapeutics, 2012
- Compliance with pregnancy prevention programmes of isotretinoin in Europe: a systematic reviewBritish Journal of Dermatology, 2011
- Risk Management Plans: are they a tool for improving drug safety?European Journal of Clinical Pharmacology, 2010
- Evaluation of Post-Authorization Safety Studies in the First Cohort of EU Risk Management Plans at Time of Regulatory ApprovalDrug Safety, 2009
- Balancing early market access to new drugs with the need for benefit/risk data: a mounting dilemmaNature Reviews Drug Discovery, 2008
- Influence of Regulatory Measures on the Rate of Spontaneous Adverse Drug Reaction Reporting in ItalyDrug Safety, 2008
- RevAssist®Drug Safety, 2008
- A Pregnancy-Prevention Program in Women of Childbearing Age Receiving IsotretinoinThe New England Journal of Medicine, 1995